Exact Mass: 383.1885

Exact Mass Matches: 383.1885

Found 124 metabolites which its exact mass value is equals to given mass value 383.1885, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Dihydrozeatin-O-glucoside

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2S)-2-methyl-4-[(3H-purin-6-yl)amino]butoxy]oxane-3,4,5-triol

C16H25N5O6 (383.1805)


Dihydrozeatin-O-glucoside belongs to the class of organic compounds known as fatty acyl glycosides of mono- and disaccharides. Fatty acyl glycosides of mono- and disaccharides are compounds composed of a mono- or disaccharide moiety linked to one hydroxyl group of a fatty alcohol, a phosphorylated alcohol (phosphoprenol), or a hydroxy fatty acid, or to one carboxyl group of a fatty acid (ester linkage) or an amino alcohol. Dihydrozeatin-O-glucoside is an extremely weak basic (essentially neutral) compound (based on its pKa). Dihydrozeatin-O-glucoside is the product of the O-glucosylation of dihydrozeatin in the cytokinin O-glucosylation. The O-glucosylation is reversible and resistant to beta-glucosidases. This reaction only shuts the physiological activity of the molecule temporarily, and is a way to store a molecule. A human metabolite taken as a putative food compound of mammalian origin [HMDB]. Dihydrozeatin-O-glucoside is found in many foods, some of which are tarragon, swede, mamey sapote, and oil-seed camellia.

   

Dihydrozeatin-9-N-glucoside

(2R,3R,4S,5S,6R)-2-(6-{[(3S)-4-hydroxy-3-methylbutyl]amino}-9H-purin-9-yl)-6-(hydroxymethyl)oxane-3,4,5-triol

C16H25N5O6 (383.1805)


Dihydrozeatin-9-N-glucoside belongs to the class of organic compounds known as glycosylamines. Glycosylamines are compounds consisting of an amine with a beta-N-glycosidic bond to a carbohydrate, thus forming a cyclic hemiaminal ether bond (alpha-amino ether). Dihydrozeatin-9-N-glucoside is possibly neutral. Dihydrozeatin-9-N-glucoside is involved in cytokinin 9-N-glucoside biosynthesis and is also involved in cytokinin-O-glucoside biosynthesis as a precursor to dihydrozeatin-9-N-glucoside-O-glucoside. N-Glucosylation at the 9-position is similar to the N-glucosylation at the 7-position. A human metabolite taken as a putative food compound of mammalian origin [HMDB]. Dihydrozeatin-9-N-glucoside is found in many foods, some of which are tronchuda cabbage, pear, persian lime, and turmeric.

   

Dihydrozeatin-7-N-glucoside

(2R,3R,4S,5S,6R)-2-(6-{[(3S)-4-hydroxy-3-methylbutyl]amino}-7H-purin-7-yl)-6-(hydroxymethyl)oxane-3,4,5-triol

C16H25N5O6 (383.1805)


Dihydrozeatin-7-N-glucoside (CAS: 91599-03-0) belongs to the class of organic compounds known as glycosylamines. Glycosylamines are compounds consisting of an amine with a beta-N-glycosidic bond to a carbohydrate, thus forming a cyclic hemiaminal ether bond (alpha-amino ether). Dihydrozeatin-7-N-glucoside is a strong basic compound (based on its pKa). Dihydrozeatin-7-N-glucoside is involved in cytokinin 7-N glucoside biosynthesis in plants as a product of the N-glucosylation of dihydrozeatin by UDP-glucose. When plants are exposed to a high concentration of cytokinins many are conjugated into 7-N glucosides. The addition to the N position decreases the physiological activity of the cytokine. Therefore, N-glucosylation may be a strategy of detoxification for plants. N-Glucosylation is common in radish.

   

N'-[2-(Oxidanylcarbamoyl)phenyl]-N-phenyl-octanediamide

N-[2-(dihydroxycarbonimidoyl)phenyl]-N-phenyloctanediimidate

C21H25N3O4 (383.1845)


   

Dihydrozeatin O-beta-D-Glucoside

2-(hydroxymethyl)-6-{2-methyl-4-[(7H-purin-6-yl)amino]butoxy}oxane-3,4,5-triol

C16H25N5O6 (383.1805)


Dihydrozeatin o-beta-d-glucoside is a member of the class of compounds known as fatty acyl glycosides of mono- and disaccharides. Fatty acyl glycosides of mono- and disaccharides are compounds composed of a mono- or disaccharide moiety linked to one hydroxyl group of a fatty alcohol or of a phosphorylated alcohol (phosphoprenols), a hydroxy fatty acid or to one carboxyl group of a fatty acid (ester linkage) or to an amino alcohol. Dihydrozeatin o-beta-d-glucoside is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Dihydrozeatin o-beta-d-glucoside can be found in soy bean, which makes dihydrozeatin o-beta-d-glucoside a potential biomarker for the consumption of this food product.

   

Antibiotic BN 186B

Antibiotic BN 186B

C14H29N3O9 (383.1904)


   
   

Chlorolissoclimide

Chlorolissoclimide

C20H30ClNO4 (383.1863)


   
   
   

Dihydrozeatin O-glucoside

Dihydrozeatin O-glucoside

C16H25N5O6 (383.1805)


   
   
   
   

scaevodimerine A

scaevodimerine A

C21H25N3O4 (383.1845)


   
   

3,7-diacetyl-intermedine|3,7-Diacetylintermedine|3,7-Diacetyllycopsamine|Di-O-acetylindicin

3,7-diacetyl-intermedine|3,7-Diacetylintermedine|3,7-Diacetyllycopsamine|Di-O-acetylindicin

C19H29NO7 (383.1944)


   

Antibiotic LL-AM 31gammar

Antibiotic LL-AM 31gammar

C14H29N3O9 (383.1904)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

dihydrozeatin-9-b-D-glucoside

dihydrozeatin-9-b-D-glucoside

C16H25N5O6 (383.1805)


   

Gly Asn Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C16H25N5O6 (383.1805)


   

Gly Pro Asn Pro

(2S)-1-[(2S)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

C16H25N5O6 (383.1805)


   

Gly Pro Pro Asn

(2S)-2-{[(2S)-1-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

C16H25N5O6 (383.1805)


   
   
   
   

Asn Gly Pro Pro

(2S)-1-{[(2S)-1-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetyl}pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C16H25N5O6 (383.1805)


   

Asn Pro Gly Pro

(2S)-1-(2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}acetyl)pyrrolidine-2-carboxylic acid

C16H25N5O6 (383.1805)


   

Asn Pro Pro Gly

2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}acetic acid

C16H25N5O6 (383.1805)


   
   
   

Pro Gly Asn Pro

(2S)-1-[(2S)-3-carbamoyl-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}propanoyl]pyrrolidine-2-carboxylic acid

C16H25N5O6 (383.1805)


   

Pro Gly Pro Asn

(2S)-3-carbamoyl-2-{[(2S)-1-{2-[(2S)-pyrrolidin-2-ylformamido]acetyl}pyrrolidin-2-yl]formamido}propanoic acid

C16H25N5O6 (383.1805)


   

Pro Asn Gly Pro

(2S)-1-{2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]acetyl}pyrrolidine-2-carboxylic acid

C16H25N5O6 (383.1805)


   

Pro Asn Pro Gly

2-{[(2S)-1-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanoyl]pyrrolidin-2-yl]formamido}acetic acid

C16H25N5O6 (383.1805)


   

Pro Pro Gly Asn

(2S)-3-carbamoyl-2-(2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}acetamido)propanoic acid

C16H25N5O6 (383.1805)


   

Pro Pro Asn Gly

2-[(2S)-3-carbamoyl-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}propanamido]acetic acid

C16H25N5O6 (383.1805)


   
   
   

Dihydrozeatin-7-N-dihydrozeatin

Dihydrozeatin-7-N-dihydrozeatin

C16H25N5O6 (383.1805)


   

Dihydrozeatin-9-N-glucoside

Dihydrozeatin-9-N-glucoside

C16H25N5O6 (383.1805)


   

Dihydrozeatin-O-glucoside

Dihydrozeatin-O-glucoside

C16H25N5O6 (383.1805)


   

1-(diphenylmethyl)azetidin-3-yl 2-carbamimidoylacetate acetate

1-(diphenylmethyl)azetidin-3-yl 2-carbamimidoylacetate acetate

C21H25N3O4 (383.1845)


   

1-(Diphenylmethyl)-3-azetidinyl 3,3-diaminoacrylate acetate (1:1)

1-(Diphenylmethyl)-3-azetidinyl 3,3-diaminoacrylate acetate (1:1)

C21H25N3O4 (383.1845)


   

4-Cyanobiphenyl-4-hexylbenzoate

4-Cyanobiphenyl-4-hexylbenzoate

C26H25NO2 (383.1885)


   

Technetium tc 99m exametazime

Technetium tc 99m exametazime

C13H25N4O3Tc (383.1927)


D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D019275 - Radiopharmaceuticals C1446 - Radiopharmaceutical Compound > C2124 - Radioconjugate

   

L-Alanyl-L-phenylalanyl-L-phenylalanine

L-Alanyl-L-phenylalanyl-L-phenylalanine

C21H25N3O4 (383.1845)


   

dihydrozeatin-7-N-glucose

dihydrozeatin-7-N-glucose

C16H25N5O6 (383.1805)


   

(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersonine

(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersonine

C22H27N2O4+ (383.1971)


   

(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2S)-2-methyl-4-(7H-purin-6-ylamino)butoxy]oxane-3,4,5-triol

(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2S)-2-methyl-4-(7H-purin-6-ylamino)butoxy]oxane-3,4,5-triol

C16H25N5O6 (383.1805)


   

(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[6-[[(3S)-4-hydroxy-3-methylbutyl]amino]purin-9-yl]oxane-3,4,5-triol

(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[6-[[(3S)-4-hydroxy-3-methylbutyl]amino]purin-9-yl]oxane-3,4,5-triol

C16H25N5O6 (383.1805)


   

3-Epoxy-16-methoxy-2,3-dihydrotabersonine

3-Epoxy-16-methoxy-2,3-dihydrotabersonine

C22H27N2O4+ (383.1971)


   

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2S)-2-methyl-4-(7H-purin-6-ylamino)butoxy]oxane-3,4,5-triol

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2S)-2-methyl-4-(7H-purin-6-ylamino)butoxy]oxane-3,4,5-triol

C16H25N5O6 (383.1805)


   

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[6-[[(3S)-4-hydroxy-3-methylbutyl]amino]purin-9-yl]oxane-3,4,5-triol

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[6-[[(3S)-4-hydroxy-3-methylbutyl]amino]purin-9-yl]oxane-3,4,5-triol

C16H25N5O6 (383.1805)


   

Dihydrozeatin O-beta-D-glucoside

Dihydrozeatin O-beta-D-glucoside

C16H25N5O6 (383.1805)


   

Dihydrozeatin-7-N-glucoside

Dihydrozeatin-7-N-glucoside

C16H25N5O6 (383.1805)


   

2-(1-Imidazolyl)-4-phenyl-6-(4-phenyl-1-piperazinyl)-1,3,5-triazine

2-(1-Imidazolyl)-4-phenyl-6-(4-phenyl-1-piperazinyl)-1,3,5-triazine

C22H21N7 (383.1858)


   

7-(Diethylaminomethyl)-1-(4-methoxyphenyl)-2-methyl-3-nitro-6-indolol

7-(Diethylaminomethyl)-1-(4-methoxyphenyl)-2-methyl-3-nitro-6-indolol

C21H25N3O4 (383.1845)


   
   

1-(4-amino-1,2,5-oxadiazol-3-yl)-5-[(dimethylamino)methyl]-N-(3-phenylpropylideneamino)-4-triazolecarboxamide

1-(4-amino-1,2,5-oxadiazol-3-yl)-5-[(dimethylamino)methyl]-N-(3-phenylpropylideneamino)-4-triazolecarboxamide

C17H21N9O2 (383.1818)


   

N-(1-tert-butyl-5-benzimidazolyl)-3,4,5-trimethoxybenzamide

N-(1-tert-butyl-5-benzimidazolyl)-3,4,5-trimethoxybenzamide

C21H25N3O4 (383.1845)


   
   

N-[[(2R,3R,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide

N-[[(2R,3R,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide

C21H25N3O4 (383.1845)


   

N-[[(2R,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide

N-[[(2R,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide

C21H25N3O4 (383.1845)


   

N-[[(2S,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide

N-[[(2S,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide

C21H25N3O4 (383.1845)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

N-[(2S)-2-hydroxy-2-(1,2,3,4-tetrahydronaphthalen-2-ylamino)ethyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide

N-[(2S)-2-hydroxy-2-(1,2,3,4-tetrahydronaphthalen-2-ylamino)ethyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide

C20H25N5O3 (383.1957)


   

7-(alpha-D-glucosyl)dihydrozeatin

7-(alpha-D-glucosyl)dihydrozeatin

C16H25N5O6 (383.1805)


An N-glycosyldihydrozeatin in which the glycosyl fragment is an alpha-D-glucopyranosyl residue located at position 7.

   

(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersoninium

(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersoninium

C22H27N2O4 (383.1971)


An indole alkaloid cation that is the conjugate acid of (3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersonine, obtained by protonation of the tertiary amino group. Major species at pH 7.3.

   
   

CC214-2

CC214-2

C20H25N5O3 (383.1957)


CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo[1][2]. CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo[1][2].

   

(1r,4s,5r,6r,7r,11z)-4-ethyl-5,7-dihydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione

(1r,4s,5r,6r,7r,11z)-4-ethyl-5,7-dihydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione

C19H29NO7 (383.1944)


   

[7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl 3-(acetyloxy)-2-hydroxy-2-isopropylbutanoate

[7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl 3-(acetyloxy)-2-hydroxy-2-isopropylbutanoate

C19H29NO7 (383.1944)


   

n-[(2s,3s,4s,5r,6r)-6-{[(2s,3s,4r,5s)-1,4-diamino-2,5,6-trihydroxyhexan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]ethanimidic acid

n-[(2s,3s,4s,5r,6r)-6-{[(2s,3s,4r,5s)-1,4-diamino-2,5,6-trihydroxyhexan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]ethanimidic acid

C14H29N3O9 (383.1904)


   

4-({2-imino-5-[(4-methoxyphenyl)methyl]-3-methyl-1h-imidazol-4-yl}methyl)-2,6-dimethoxyphenol

4-({2-imino-5-[(4-methoxyphenyl)methyl]-3-methyl-1h-imidazol-4-yl}methyl)-2,6-dimethoxyphenol

C21H25N3O4 (383.1845)


   

3-[2-(7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl)-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

3-[2-(7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl)-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

C20H30ClNO4 (383.1863)


   

3-{[2,6-dihydroxy-3-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

3-{[2,6-dihydroxy-3-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O4 (383.1845)


   

(1s,9r,14s)-15-hydroxy-2,11-dimethoxy-14-methyl-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one

(1s,9r,14s)-15-hydroxy-2,11-dimethoxy-14-methyl-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one

C21H25N3O4 (383.1845)


   

n-[(3s,6r)-6-{[(2s,3s,4r,5s)-1,4-diamino-2,5,6-trihydroxyhexan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]ethanimidic acid

n-[(3s,6r)-6-{[(2s,3s,4r,5s)-1,4-diamino-2,5,6-trihydroxyhexan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]ethanimidic acid

C14H29N3O9 (383.1904)


   

3-{[2,6-dihydroxy-3-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

3-{[2,6-dihydroxy-3-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O4 (383.1845)


   

(4as,6s,7r,7as)-4-(methoxycarbonyl)-7-methyl-1h,2h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyridin-6-yl (1s)-1-methyl-1,2-dihydro-2,7-naphthyridine-4-carboxylate

(4as,6s,7r,7as)-4-(methoxycarbonyl)-7-methyl-1h,2h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyridin-6-yl (1s)-1-methyl-1,2-dihydro-2,7-naphthyridine-4-carboxylate

C21H25N3O4 (383.1845)


   

4-(methoxycarbonyl)-7-methyl-1h,2h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyridin-6-yl 1-methyl-1,2-dihydro-2,7-naphthyridine-4-carboxylate

4-(methoxycarbonyl)-7-methyl-1h,2h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyridin-6-yl 1-methyl-1,2-dihydro-2,7-naphthyridine-4-carboxylate

C21H25N3O4 (383.1845)


   

[(7r,7ar)-7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-[(1s)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

[(7r,7ar)-7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-[(1s)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

C19H29NO7 (383.1944)


   

4-ethyl-5,7-dihydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione

4-ethyl-5,7-dihydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione

C19H29NO7 (383.1944)


   

(3r)-3-[(1s)-2-[(1r,3s,4as,7s,8ar)-7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

(3r)-3-[(1s)-2-[(1r,3s,4as,7s,8ar)-7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

C20H30ClNO4 (383.1863)


   

(3r)-3-[(1s)-2-[(1r,3s,4as,7s,8as)-7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

(3r)-3-[(1s)-2-[(1r,3s,4as,7s,8as)-7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

C20H30ClNO4 (383.1863)


   

tert-butyl 3-{[(3s,8as)-1-hydroxy-4-oxo-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-3-yl]methyl}indole-1-carboxylate

tert-butyl 3-{[(3s,8as)-1-hydroxy-4-oxo-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-3-yl]methyl}indole-1-carboxylate

C21H25N3O4 (383.1845)


   

6-({2-imino-5-[(4-methoxyphenyl)methyl]-3-methyl-1h-imidazol-4-yl}methyl)-2,3-dimethoxyphenol

6-({2-imino-5-[(4-methoxyphenyl)methyl]-3-methyl-1h-imidazol-4-yl}methyl)-2,3-dimethoxyphenol

C21H25N3O4 (383.1845)


   

(3s,8as)-3-{[(3s)-2,6-dihydroxy-3-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

(3s,8as)-3-{[(3s)-2,6-dihydroxy-3-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O4 (383.1845)


   

(2s,3s,4r,5s,6r)-2-(hydroxymethyl)-6-({[(2r)-4-(3h-purin-6-ylamino)butan-2-yl]oxy}methyl)oxane-3,4,5-triol

(2s,3s,4r,5s,6r)-2-(hydroxymethyl)-6-({[(2r)-4-(3h-purin-6-ylamino)butan-2-yl]oxy}methyl)oxane-3,4,5-triol

C16H25N5O6 (383.1805)


   

15-hydroxy-2,11-dimethoxy-14-methyl-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one

15-hydroxy-2,11-dimethoxy-14-methyl-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one

C21H25N3O4 (383.1845)


   

(3s,8as)-3-{[(3s)-2,6-dihydroxy-3-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

(3s,8as)-3-{[(3s)-2,6-dihydroxy-3-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O4 (383.1845)


   

(3r)-3-[(1s)-2-[(1s,4r,4as,7s,8ar)-7-chloro-4-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

(3r)-3-[(1s)-2-[(1s,4r,4as,7s,8ar)-7-chloro-4-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

C20H30ClNO4 (383.1863)